



NEWS RELEASE

CareDx and QIAGEN Enter Into Commercial Collaboration to Enhance HLA Lab Experience Using QIAxcel Instrumentation and CareDx HLA Typing Technology

Brisbane, CA—May 31, 2016—CareDx, Inc. (Nasdaq: CDNA), a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced it has signed a memorandum of understanding to collaborate with QIAGEN, the leading provider of Sample to Insight solutions for the life sciences and diagnostics industry.

Under the terms of this commercial collaboration, CareDx will make available to Human Leukocyte Antigen (HLA) laboratories worldwide the proprietary QIAGEN QIAxcel Advanced Instrumentation together with its proprietary Olerup SSP® kits and SCORE™ software. This combined offering will provide transplant labs an additional option for processing and data entry for HLA typing.

“We are excited to be working with QIAGEN, a leader in diagnostic technology. This collaboration fits well with our strategy to partner with leading innovative solution providers and enhance the transplant lab testing workflow,” said Anders Karlsson, Chief International Business Officer at CareDx.

“CareDx is a recognized leader in transplant diagnostics. Our collaboration will allow us to bring our QIAxcel solutions to HLA labs around the globe using the CareDx commercial channel,” said Thierry Bernard, Senior Vice President and Head of QIAGEN’s Molecular Diagnostics Business Area.

Financial terms of the collaboration were not disclosed.

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. The company markets AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure™, a proprietary next-generation sequencing–based test to detect donor-derived cell-free DNA after transplantation.

CareDx, with its presence through Olerup AB, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP®, a set of HLA typing is used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation; and XM-ONE®, the first standardized test that quickly identifies a patient’s antigens against HLA Class I, Class II or antibodies against a donor’s endothelium. For more information, please visit: www.CareDx.com.

Media Contacts – CareDx

Molly Martell, Senior Director, Marketing

T: +1 415-728-6307

E: [mmartell@caredx.com](mailto:mmartell@ caredx.com)

Media Contacts - Investor

Jamar Ismail, Vice President

Westwicke Partners, LLC

T: +1 415-513-1282

E: jamar.ismail@westwicke.com

Forward Looking Statements

In addition to the historical information, this press release contains forward-looking statements with respect to our business, research, development and commercialization efforts and anticipated future financial results. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties. These factors, together with those that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.